PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.420
-0.020 (-1.39%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013.
PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
PMV Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2013 |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | David Mack |
Contact Details
Address: 400 Alexander Park Drive, Suite 301 Princeton, New Jersey 08540 United States | |
| Phone | 609 642 6670 |
| Website | pmvpharma.com |
Stock Details
| Ticker Symbol | PMVP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001699382 |
| CUSIP Number | 69353Y103 |
| ISIN Number | US69353Y1038 |
| Employer ID | 46-3218129 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David H. Mack Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Independent Director and Member of Scientific Advisory Board |
| Michael Carulli | Chief Financial Officer |
| Dr. Deepika Jalota Pharm.D. | Chief Development Officer |
| Robert Ticktin J.D. | General Counsel, Chief Operating Officer and Company Secretary |
| Tim Smith M.B.A. | Senior Vice President and Head of Corporate Development and Investor Relations |
| Crystal Zuckerman | Vice President of Human Resources |
| Dr. Binh Vu Ph.D. | Senior Vice President of Drug Discovery and CMC |
| Dr. Marc Fellous M.D. | Senior Vice President and Head of Clinical Development and Medical Affairs |
| Laura De Leon | Vice President and Head of Clinical Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | ARS | Filing |
| Apr 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 10-K | Annual Report |
| Mar 4, 2026 | SCHEDULE 13D/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | 10-Q | Quarterly Report |